<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03772613</url>
  </required_header>
  <id_info>
    <org_study_id>18-005209</org_study_id>
    <nct_id>NCT03772613</nct_id>
  </id_info>
  <brief_title>The Randomized OPTIMAL-ACT Trial</brief_title>
  <official_title>Optimal Target of Activated Clotting Time During Percutaneous Coronary Intervention and Outcomes: The Randomized OPTIMAL-ACT Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mayo Clinic</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Mayo Clinic</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Despite the widespread adoption of recommended anticoagulation intensity ranges during
      percutaneous coronary intervention (PCI), there are limited randomized clinical trials
      testing specific targets for activated clotting times (ACT). The primary research hypothesis
      is that in the modern cardiac catheterization laboratory, where PCI procedural duration is
      relatively short, radial access with small caliber equipment is preferable, and where rates
      of intracoronary stenting and dual antiplatelet therapy use is high, lower ACT targets, as
      compared with higher ACT targets, will be associated with lower rates of bleeding while
      having similar rates of ischemic events.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 8, 2019</start_date>
  <completion_date type="Anticipated">January 2022</completion_date>
  <primary_completion_date type="Anticipated">January 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Primary Study Endpoint: Bleeding</measure>
    <time_frame>From date of randomization until the date of first documented bleeding event up to 24 hours</time_frame>
    <description>Count of any individuals experiencing any of the following: Bleeding Academic Research Consortium (BARC) 1, 2, 3 or 5 or EASY hematoma classification after transradial/ulnar procedures (I-V)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Primary Safety Endpoint: Composite of Net Adverse Clinical Events (NACE)</measure>
    <time_frame>From date of randomization until the date of first documented NACE event (all-cause mortality, myocardial infarction, stroke, target lesion revascularization, or major bleeding) , whichever came first, assessed up to 30 days.</time_frame>
    <description>Count of individuals experiencing any of the following: all-cause mortality, myocardial infarction, stroke, target lesion revascularization, or major bleeding</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Stent Thrombosis</measure>
    <time_frame>From date of randomization until the date of first documented stent thrombosis, assessed up to 30 days.</time_frame>
    <description>Count of individuals who experience stent thrombosis</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">546</enrollment>
  <condition>Coronary Artery Disease</condition>
  <condition>Ischemic Heart Disease</condition>
  <condition>Anticoagulant-induced Bleeding</condition>
  <condition>Coronary Syndrome</condition>
  <arm_group>
    <arm_group_label>Low ACT Target</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>ACT target range of 225 to 275 seconds is achieved prior to PCI if no planned glycoprotein IIb/IIIa inhibitor used</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Medium ACT Target</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>ACT target range of 275 to 325 seconds is achieved prior to PCI if no planned glycoprotein IIb/IIIa inhibitor used</description>
  </arm_group>
  <arm_group>
    <arm_group_label>High ACT Target</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>ACT target range of 325 to 375 seconds is achieved prior to PCI if no planned glycoprotein IIb/IIIa inhibitor used</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Unfractionated heparin</intervention_name>
    <description>Administration of unfractionated heparin will be assessed using the activated clotting time</description>
    <arm_group_label>High ACT Target</arm_group_label>
    <arm_group_label>Low ACT Target</arm_group_label>
    <arm_group_label>Medium ACT Target</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age&gt;18

          -  Referred for coronary angiography with possible coronary revascularization or
             adjunctive invasive diagnostic testing (IVUS/OCT, FFR, or iFR)

        Exclusion Criteria:

          -  Receipt of LMWH at treatment dose (not DVT prophylaxis dose) within 6 hours of
             coronary angiography

          -  Prior GP IIb/IIIa use within the previous 72 hours

          -  Use of warfarin (vitamin K antagonist) or direct oral anticoagulant

          -  Patients on LMWH bridging strategy

          -  PCI within prior 30 days

          -  Planned use of bivalirudin as the procedural anticoagulant

          -  Rotational atherectomy

          -  Excimer laser coronary angioplasty

          -  Chronic total occlusions

          -  Patients with active bleeding disorders or bleeding diathesis

          -  Patients with ST-segment elevation myocardial infarction

          -  Patient with clinical evidence of cardiogenic shock (defined as SBP&lt;90 mmHg for ≥30
             min OR support to maintain SBP ≥90 mmHg AND evidence of end-organ hypoperfusion (urine
             output &lt;30 mL/h or cool extremities)

          -  Chronic kidney disease stage 4/5 (GFR 30 mL/min)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Shahyar M Gharacholou, MD, MSc</last_name>
    <role>Principal Investigator</role>
    <affiliation>Mayo Clinic</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Mayo Clinic in Florida</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32224</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michael Gharacholou, MD</last_name>
      <phone>904-953-2000</phone>
      <email>gharacholou.shahyar@mayo.edu</email>
    </contact>
    <investigator>
      <last_name>Shahyar M Gharacholou</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://www.mayo.edu/research/clinical-trials</url>
    <description>Mayo Clinic Clinical Trials</description>
  </link>
  <verification_date>October 2019</verification_date>
  <study_first_submitted>December 8, 2018</study_first_submitted>
  <study_first_submitted_qc>December 10, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">December 11, 2018</study_first_posted>
  <last_update_submitted>October 11, 2019</last_update_submitted>
  <last_update_submitted_qc>October 11, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">October 15, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Mayo Clinic</investigator_affiliation>
    <investigator_full_name>Shahyar M. Gharacholou</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>activated clotting time</keyword>
  <keyword>outcomes</keyword>
  <keyword>bleeding</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Coronary Artery Disease</mesh_term>
    <mesh_term>Myocardial Ischemia</mesh_term>
    <mesh_term>Heart Diseases</mesh_term>
    <mesh_term>Hemorrhage</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heparin</mesh_term>
    <mesh_term>Calcium heparin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

